Good MorningEquities rebounded again on Thursday but there is a growing list of companies giving reasons why the rally shouldn't be trusted. The key takeaways from earnings reports this weak are that near-term headwinds are growing because of the Ukrainian conflict and they may worsen as the war wears on. Not only is the conflict causing a spike in energy prices but it is also putting a strain on an already struggling supply chain. What this means for S&P 500 companies is a negative impact to the top and bottom line, declining expectations for revenue and earnings, and lower prices for the S&P 500 index.
Friday's market action will be driven by geopolitical sentiment and Fedspeak. There are at least 4 Fed members on the schedule to make remarks and each will be closely watched for clues about interest rates. Fed chief Jerome Powell surprised the market earlier in the week when he gave a more hawkish opinion of the inflation outlook than what was expected and now the market is pricing in a 50 basis point hike at the next FOMC meeting. Featured: Elon Musk's Next AI Partnership Could Shake Up This Stock (Ad) 
|
Consumer Discretionary | |
This might not be a question you were expecting to hear with regards to NIO (NYSE: NIO), whose shares are down almost 70% from last year’s all-time high, but it’s one worth asking. Because if one thing’s for sure, the Shanghai headquartered electric vehicle (EV) maker knows how t... Read the Full Story |
|
From Our Partners | | In 1974, a quiet deal between Henry Kissinger and the Saudis reshaped America's monetary order overnight, with no announcement and no vote in Congress.
Decades later, the dollar had lost more than 84% of its purchasing power even as millionaire ranks surged into the millions.
Financial reporter Kimi Weintraub sits down to explore a new, largely unnoticed shift in America's monetary system, one tied to executive orders and a reported 13-nation agreement. | | Watch the full interview before the December 14 Miami summit |
|
Consumer Discretionary | |
Darden Restaurants International Is Another Reason Not To Trust The Rally
Darden Restaurants (NYSE: DRI) gave the market another reason not to trust the rebound in equities when it reported earnings. The company not only missed on the top and bottom lines but tightened its guidance to a range be... Read the Full Story |
|
Consumer Discretionary | |
But wait for confirmation before going on the long side of OLLI stock
Ollie’s Bargain Outlet Holdings (NASDAQ: OLLI) delivered another disappointing earnings report. However, investors may be signaling that the sell-off of OLLI stock is overdone. The stock price has been consolidating in t... Read the Full Story |
|
From Our Partners | | MindWalk Holdings (NASDAQ: HYFT) is applying AI to drug discovery, and its customer base already includes 19 of the top 20 global pharmaceutical companies.
The company's HYFT technology maps roughly 660 million biological patterns and 25 billion relationships. Q1 fiscal 2027 revenue hit $3.8 million, with gross margin improving to 59 percent in its fifth consecutive quarter of year-over-year growth.
A new OpenFold3 deployment delivered about 5x faster antibody-antigen inference, and a $30 million revolving credit line, free of warrants or equity conversion, adds fuel for expansion. | | Take a closer look at HYFT before AI reshapes drug discovery. |
|
Energy | | What to do when eastern Europe suddenly erupts into violence? Griping about the cost of gasoline (has anyone else shifted to filling up when the tank is half full?) has its cathartic moments, but it's also important to remember that whole countries are living in fear right now.
Even so, beyond dona... Read the Full Story |
|
Healthcare | |
There will always be a need for healthcare. Doctor visits, prescriptions, medical equipment, and of course, vaccines will remain fixtures in our society for decades to come.
This is what makes the defensive healthcare sector a good place to park funds for the long-term. Regardless of the economi... Read the Full Story |
|
From Our Partners | | When Moonshot AI's new model rattled overnight markets, stocks gapped down 1 percent before the open, and history shows the story doesn't end there.
Between 9 30 and 9 50 AM, Wall Street settles nearly 25 percent of the day's total volume in a single 20 minute window, often revealing market direction for the rest of the morning.
A former money manager breaks down the floor data behind this pattern, including a June 25th session where inflation surged past 4 percent and the market moved just 0.3 percent afterward. | | Watch the full video breakdown before access is taken down |
|
Markets | | 3D printing and digital manufacturing solutions provider 3D Systems (NASDAQ: DDD) stock has sold-off over (-60%) from its pandemic high of $56.50. The maker of 3D printing systems has seen growing mainstream adaption of the technology from the aerospace, automotive, electronics, manufacturing, indus... Read the Full Story |
|
Markets | | Gaming technology services and products maker International Gaming Technology (NYSE: IGT) stock has held up relatively well in 2022 despite the benchmark indices sell-off. While the Omicron variant impacted some markets with labor shortages, supply chain pressures and cost inflation, IGT still manag... Read the Full Story |
|
Finance | |
Factset Research Systems Slips On Solid Results
The price action in Factset Research Systems (NYSE: FDS) underwent a correction over the past few months but it looks like that time is now behind us. The correction was due to uncertainty over the future, uncertainty over acquisition, and no small... Read the Full Story |
|
Materials | |
H.B. Fuller Seals The Deal On Inflation
If you were worried about inflation taming in the second half of the year H.B. Fuller (NYSE: FUL) has laid those fear to rest. The report from H.B. Fuller, a manufacturer of specialty adhesive chemicals worldwide, guarantees input costs are going to go up ... Read the Full Story |
|
Technology | |
These 3 Semi Stocks Should Be On Your Radar
Finding valid reasons to invest in semiconductor stocks is certainly not difficult. These tiny chips are critical for powering up some of the most exciting technology today, including smartphones, data centers, and even electric vehicles. Then you have ... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. | | View Today's Stock Pick |
|
